Arch Biopartners Inc (ACHFF)
1.23
-0.02
(-1.60%)
USD |
OTCM |
May 31, 16:00
Arch Biopartners Net Income (Quarterly): -0.5754M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.5754M |
| September 30, 2023 | 0.182M |
| June 30, 2023 | -0.3351M |
| March 31, 2023 | -0.7113M |
| December 31, 2022 | -1.589M |
| September 30, 2022 | -0.3814M |
| June 30, 2022 | -0.1936M |
| March 31, 2022 | -0.3848M |
| December 31, 2021 | -0.1386M |
| September 30, 2021 | 0.529M |
| June 30, 2021 | 0.7143M |
| March 31, 2021 | -0.8304M |
| December 31, 2020 | -1.268M |
| September 30, 2020 | -1.208M |
| June 30, 2020 | -1.58M |
| March 31, 2020 | -0.0711M |
| December 31, 2019 | -0.5553M |
| September 30, 2019 | -0.5367M |
| June 30, 2019 | -0.0386M |
| March 31, 2019 | -0.3863M |
| December 31, 2018 | -0.6188M |
| September 30, 2018 | -0.4619M |
| June 30, 2018 | -1.152M |
| March 31, 2018 | -0.4625M |
| December 31, 2017 | -0.2687M |
| Date | Value |
|---|---|
| September 30, 2017 | -0.1757M |
| June 30, 2017 | -0.9711M |
| March 31, 2017 | -0.1165M |
| December 31, 2016 | -0.1764M |
| September 30, 2016 | -0.2756M |
| June 30, 2016 | -0.1419M |
| March 31, 2016 | -0.2352M |
| December 31, 2015 | -0.1168M |
| September 30, 2015 | -0.1117M |
| June 30, 2015 | -0.1349M |
| March 31, 2015 | -0.1358M |
| December 31, 2014 | -0.3156M |
| September 30, 2014 | -0.1434M |
| June 30, 2014 | -0.12M |
| March 31, 2014 | -0.0532M |
| December 31, 2013 | -0.0504M |
| September 30, 2013 | -0.0568M |
| June 30, 2013 | -0.0177M |
| March 31, 2013 | -0.0796M |
| December 31, 2012 | -0.0329M |
| September 30, 2012 | -0.0934M |
| June 30, 2012 | -0.1029M |
| March 31, 2012 | -0.0597M |
| December 31, 2011 | -0.0852M |
| September 30, 2011 | -0.0999M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-1.589M
Minimum
Dec 2022
0.7143M
Maximum
Jun 2021
-0.4722M
Average
-0.3848M
Median
Mar 2022
Net Income (Quarterly) Benchmarks
| Acasti Pharma Inc | -2.391M |
| Aurinia Pharmaceuticals Inc | -26.88M |
| Edesa Biotech Inc | -1.861M |
| Lexaria Bioscience Corp | -0.6495M |
| Xenon Pharmaceuticals Inc | -47.93M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 0.5166M |
| EPS Diluted (Quarterly) | -0.0095 |
| Enterprise Value | 80.76M |
| Earnings Yield | -1.86% |
| Normalized Earnings Yield | -4.622 |